Metastatic Prostate Cancer study: JNJ-101556143 Formulation
Official title Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
ClinicalTrials.gov ID: NCT06800313
What this study is testing
What is JNJ-101556143 Formulation 1?
This is an investigational oral medicine being studied as a potential treatment for metastatic prostate cancer.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study checks if the drug is safe and if it helps treat the cancer.
- Who it's for
- Men with prostate cancer that has spread to other parts of the body and stopped responding to previous treatments.
- What's involved
- Participants will receive the study drug and undergo regular medical tests to monitor their health and the cancer.
- Time commitment
- The study duration and specific visit schedule are not listed in the provided text.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and...
- mCRPC Arms: (Phase 1 Part 1 \& 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum...
- SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next...
- mHSPC arms (Phase 2 Part 2B, 2C \& 2D) serum testosterone \>150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA...
You likely can't join if
- Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by...
- mCRPC arms: (Phase 1 Part 1 \& 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first...
- SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer
- mHSPC arms (Phase 2 Part 2B, 2C \& 2D) regional pelvic lymph node disease only
The study team makes the final eligibility decision.
Where it is enrolling
- Colorado Springs, Colorado, United States
- Denver, Colorado, United States
- New Haven, Connecticut, United States
- Sarasota, Florida, United States
- Metairie, Louisiana, United States
- Boston, Massachusetts, United States
- Grand Rapids, Michigan, United States
- Omaha, Nebraska, United States
- Long Island City, New York, United States
- Syracuse, New York, United States
- Durham, North Carolina, United States
- Myrtle Beach, South Carolina, United States
- Nashville, Tennessee, United States
- Austin, Texas, United States
- Houston, Texas, United States
- Norfolk, Virginia, United States
- Sutton, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Colorado Springs, Colorado, United States; Denver, Colorado, United States; New Haven, Connecticut, United States; Sarasota, Florida, United States; Metairie, Louisiana, United States; Boston, Massachusetts, United States and 11 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.